Syngene International shares fell 10% to Rs 674 in Thursday’s intraday trade after the company reported a 3% year-on-year decline in consolidated net profit to Rs 183 crore for Q4 FY25, compared to Rs 189 crore a year earlier.
However, Revenue for the quarter stood at Rs 1,018 crore, marking an 11% increase from Rs 916.9 crore in the same period last year.
Operationally, earnings before interest, tax, depreciation and amortisation (EBITDA) rose 8.4% year-on-year to Rs 343.6 crore, versus Rs 316 crore a year ago. EBITDA margins stood at 33.8%, lower than 34.4% in the year-ago quarter.
The board recommended a final dividend of Rs 1.25 per share for FY25, subject to shareholder approval.
Commenting on the performance, Peter Bains, Managing Director and CEO, said, “The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene’s position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market.”
He added that the company saw “robust growth” in the biologics CDMO business, supported by a mix of commercial manufacturing activity and new development projects. Syngene’s research division also contributed meaningfully to the growth, benefitting from a high rate of conversion of pilot projects into full-scale programmes in its discovery services segment.
Bains indicated that these developments position the company well for long-term growth, particularly in its biologics and research services verticals.
Also Read: Stocks in news: HUL, Axis Bank, Tata Consumer, LTIMindtree, Adani Green
Syngene International shares price target
According to Trendlyne, the average target price for the stock is Rs 844, indicating a potential upside of about 24% from current levels. The consensus recommendation from 10 analysts is ‘Buy’.
Syngene International shares price performance
The stock is down 23% year-to-date and has gained around 10% over two years. Syngene’s market cap stands at Rs 27,344 crore.
Also Read: XRP overtakes Bitcoin in trading surge, PEPE enters top 10: What’s driving India’s new crypto bets?
( Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
However, Revenue for the quarter stood at Rs 1,018 crore, marking an 11% increase from Rs 916.9 crore in the same period last year.
Operationally, earnings before interest, tax, depreciation and amortisation (EBITDA) rose 8.4% year-on-year to Rs 343.6 crore, versus Rs 316 crore a year ago. EBITDA margins stood at 33.8%, lower than 34.4% in the year-ago quarter.
The board recommended a final dividend of Rs 1.25 per share for FY25, subject to shareholder approval.
Commenting on the performance, Peter Bains, Managing Director and CEO, said, “The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene’s position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market.”
He added that the company saw “robust growth” in the biologics CDMO business, supported by a mix of commercial manufacturing activity and new development projects. Syngene’s research division also contributed meaningfully to the growth, benefitting from a high rate of conversion of pilot projects into full-scale programmes in its discovery services segment.
Bains indicated that these developments position the company well for long-term growth, particularly in its biologics and research services verticals.
Also Read: Stocks in news: HUL, Axis Bank, Tata Consumer, LTIMindtree, Adani Green
Syngene International shares price target
According to Trendlyne, the average target price for the stock is Rs 844, indicating a potential upside of about 24% from current levels. The consensus recommendation from 10 analysts is ‘Buy’.
Syngene International shares price performance
The stock is down 23% year-to-date and has gained around 10% over two years. Syngene’s market cap stands at Rs 27,344 crore.
Also Read: XRP overtakes Bitcoin in trading surge, PEPE enters top 10: What’s driving India’s new crypto bets?
( Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
